A multi-centre study comparing the effects of AZD2927 and placebo on the electrical activity in the heart in patients
Study identifier:D4120C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2011-001716-59
CTIS identifier:N/A
Study Complete
Official Title
A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of AZD2927 in Patients Undergoing an Invasive Electrophysiological Procedure
Medical condition
Arrhythmia
Phase
Phase 2
Healthy volunteers
No
Study drug
AZD2927, Placebo
Sex
All
Actual Enrollment
20
Study type
Interventional
Age
20 Years - 80 Years
Date
Study Start Date: 01 Sept 2011
Primary Completion Date: 01 Jan 2012
Study Completion Date: 01 Jan 2012
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2012 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 A single dose of AZD2927 administered as an iv infusion | Drug: AZD2927 A single dose of AZD2927 administered as an iv infusion |
| Placebo Comparator: 2 A single dose of placebo administered as an iv infusion | Drug: Placebo A single dose of placebo administered as an iv infusion |
Contacts
Investigators
Principal Investigator
Stefan C Carlsson
AstraZeneca
